DK1224264T3 - Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser - Google Patents
Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponserInfo
- Publication number
- DK1224264T3 DK1224264T3 DK00970961.9T DK00970961T DK1224264T3 DK 1224264 T3 DK1224264 T3 DK 1224264T3 DK 00970961 T DK00970961 T DK 00970961T DK 1224264 T3 DK1224264 T3 DK 1224264T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- cell lines
- immune responses
- presenting cells
- allogeneic cell
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title abstract 4
- 230000028993 immune response Effects 0.000 title abstract 4
- 230000000735 allogeneic effect Effects 0.000 title abstract 2
- 210000000612 antigen-presenting cell Anatomy 0.000 title abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464494—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- C12N5/064—Immunosuppressive dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/58—Prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15990399P | 1999-10-15 | 1999-10-15 | |
PCT/US2000/028670 WO2001029192A2 (en) | 1999-10-15 | 2000-10-16 | Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1224264T3 true DK1224264T3 (da) | 2010-05-10 |
Family
ID=22574604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00970961.9T DK1224264T3 (da) | 1999-10-15 | 2000-10-16 | Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser |
Country Status (10)
Country | Link |
---|---|
US (2) | US7988963B1 (da) |
EP (3) | EP2151245A1 (da) |
AT (1) | ATE456649T1 (da) |
AU (1) | AU8026800A (da) |
CY (1) | CY1110235T1 (da) |
DE (1) | DE60043781D1 (da) |
DK (1) | DK1224264T3 (da) |
ES (1) | ES2340358T3 (da) |
PT (1) | PT1224264E (da) |
WO (1) | WO2001029192A2 (da) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050084967A1 (en) | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
US20040022813A1 (en) * | 2002-08-05 | 2004-02-05 | Jean-Claude Bystryn | Shed antigen vaccine with dendritic cells adjuvant |
AR060424A1 (es) * | 2007-04-11 | 2008-06-18 | Consejo Nac Invest Cient Tec | Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento |
US8628762B2 (en) * | 2008-12-10 | 2014-01-14 | Icahn School Of Medicine At Mount Sinai | T-helper cell type 17 lineage-specific adjuvants, compositions and methods |
JP2014533938A (ja) | 2011-10-20 | 2014-12-18 | カリフォルニア ステム セル インコーポレイテッド | γインターフェロンを用いた抗原提示癌ワクチン |
WO2016145578A1 (en) * | 2015-03-13 | 2016-09-22 | Syz Cell Therapy Co. | Methods of cancer treatment using activated t cells |
CA3029813A1 (en) | 2016-06-13 | 2017-12-21 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
US11850279B2 (en) | 2016-07-13 | 2023-12-26 | Ohio State Innovation Foundation | Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity |
EP3678701A4 (en) | 2017-09-05 | 2021-12-01 | Torque Therapeutics, Inc. | THERAPEUTIC PROTEIN COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF |
WO2019183924A1 (en) | 2018-03-30 | 2019-10-03 | Syz Cell Therapy Co. | Improved multiple antigen specific cell therapy methods |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5637483A (en) | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
ATE260971T1 (de) | 1992-04-01 | 2004-03-15 | Univ Rockefeller | Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung |
US6077519A (en) * | 1993-01-29 | 2000-06-20 | University Of Pittsburgh | Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients |
WO1995032734A1 (en) * | 1994-05-26 | 1995-12-07 | Innogenetics N.V. | New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness |
US6300090B1 (en) * | 1994-07-29 | 2001-10-09 | The Rockefeller University | Methods of use of viral vectors to deliver antigen to dendritic cells |
EP0879281B1 (en) * | 1996-02-08 | 2005-12-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of Health and Human Services | Methods for transforming dendritic cells and activating t cells |
DE69816812T2 (de) * | 1997-05-23 | 2004-04-22 | Hadasit Medical Research Services And Development Ltd. | Non myeloablative therapie für toleranzinduktion |
WO1999042564A2 (en) | 1998-02-20 | 1999-08-26 | The Rockefeller University | Apoptotic cell-mediated antigen presentation to dendritic cells |
AU2002953094A0 (en) * | 2002-12-04 | 2002-12-19 | The University Of Queensland | Immunomodulating compositions, processes for their production and uses therefor |
-
2000
- 2000-10-16 PT PT00970961T patent/PT1224264E/pt unknown
- 2000-10-16 EP EP09014698A patent/EP2151245A1/en not_active Withdrawn
- 2000-10-16 AT AT00970961T patent/ATE456649T1/de active
- 2000-10-16 AU AU80268/00A patent/AU8026800A/en not_active Abandoned
- 2000-10-16 US US10/110,553 patent/US7988963B1/en not_active Expired - Fee Related
- 2000-10-16 ES ES00970961T patent/ES2340358T3/es not_active Expired - Lifetime
- 2000-10-16 WO PCT/US2000/028670 patent/WO2001029192A2/en active Application Filing
- 2000-10-16 DK DK00970961.9T patent/DK1224264T3/da active
- 2000-10-16 EP EP00970961A patent/EP1224264B1/en not_active Expired - Lifetime
- 2000-10-16 DE DE60043781T patent/DE60043781D1/de not_active Expired - Lifetime
- 2000-10-16 EP EP10013110A patent/EP2302038A1/en not_active Withdrawn
-
2010
- 2010-04-07 CY CY20101100319T patent/CY1110235T1/el unknown
-
2011
- 2011-06-27 US US13/169,456 patent/US20110268767A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2302038A1 (en) | 2011-03-30 |
ATE456649T1 (de) | 2010-02-15 |
US7988963B1 (en) | 2011-08-02 |
AU8026800A (en) | 2001-04-30 |
EP2151245A1 (en) | 2010-02-10 |
US20110268767A1 (en) | 2011-11-03 |
PT1224264E (pt) | 2010-03-15 |
WO2001029192A3 (en) | 2002-01-17 |
EP1224264A2 (en) | 2002-07-24 |
EP1224264B1 (en) | 2010-01-27 |
CY1110235T1 (el) | 2015-01-14 |
DE60043781D1 (de) | 2010-03-18 |
ES2340358T3 (es) | 2010-06-02 |
WO2001029192A2 (en) | 2001-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
von Spee-Mayer et al. | Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus | |
Yoshida et al. | Poly (lactic‐co‐glycolic acid) enhances maturation of human monocyte‐derived dendritic cells | |
HK1086750A1 (en) | Pharmaceutical composition for inducing an immune response in a human or animal | |
DK1224264T3 (da) | Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser | |
DK0633929T3 (da) | Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener | |
BR9610802A (pt) | Método para melhoria da resposta imunológica método de preparo de células t de antígeno específico método para induzir tolerância de tecido de enxerto auxiliar de vacina meio de expansão e preparação de células dentríticas população de células dentríticas e respectivo método de preparo método para direcionar células-tronco hematopoiéticas ou células progenitoras a uma linhagem de células dentríticas | |
DK1739166T3 (da) | Fremstilling af fødevare- eller autoantigen-specifikke Tr1-celler fra en leukocyt- eller PBMC-population | |
DK0463151T3 (da) | Frembringelse af xenogene antistoffer | |
NO986173L (no) | FremgangsmÕte for aktivering av dendrittceller | |
NO985160L (no) | Anvendelse av interleukin-10 til fremstilling av en populasjon av suppresso | |
Baruah et al. | Mice lacking C1q or C3 show accelerated rejection of minor H disparate skin grafts and resistance to induction of tolerance | |
Carpentier et al. | Extrathymic induction of Foxp3+ regulatory T cells declines with age in a T‐cell intrinsic manner | |
WO1999032634A3 (en) | Compositions derived from mycobacterium vaccae and methods for their use | |
Romano et al. | Isolation and expansion of thymus‐derived regulatory T cells for use in pediatric heart transplant patients | |
Wrammert et al. | Human immune memory to yellow fever and smallpox vaccination | |
WO2003000199A3 (en) | Ilt3 and ilt4-related compositions and methods | |
Karsten et al. | Biologic meshes and synthetic meshes in cancer patients: a double-edged sword: differences in production of IL-6 and IL-12 caused by acellular dermal matrices in human immune cells | |
Huang et al. | Efficacy of pretreatment of allografts with methoxypolyethylene glycol-succinimidyl-propionic acid ester in combination with an anti-OX40L monoclonal antibody in relieving graft-versus-host disease in mice | |
WO2001094551A3 (de) | Gen-modifizierte t-zellen, verfahren zu ihrer herstellung und ihre verwendung | |
Szabolcs | The immunobiology of cord blood transplantation | |
e Sousa et al. | Conditioning of dendritic cells by pathogen-derived stimuli | |
Bieńkowska et al. | Thymus-deriving natural regulatory T cell generation in vitro: Role of the source of activation signals | |
Pawelec et al. | Engineering anticancer T cells for extended functional longevity | |
WO2001028574A3 (en) | Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain | |
Pauels et al. | Lymphokine profile and activation pattern of two unrelated antigen‐or idiotype‐specific T suppressor cell clones |